Name: Latest research reports of Glenmark Pharmaceuticals Ltd. authored by Phillip Capital and published by - Trendlyne research reports.
Item: Glenmark Pharmaceuticals Ltd.
Rating: 5
Author: Phillip Capital

Glenmark Pharmaceuticals Ltd.

NSE: GLENMARK | BSE: 532296 | ISIN: INE935A01035 | Industry: Pharmaceuticals
| Mid-range Performer

1936.7000 9.90 (0.51%)

NSE Sep 02, 2025 12:14 PM

51.84% Gain from 52W Low

Volume: 104.6K

Glenmark Pharmaceuticals Ltd.

16 May 2016

1936.70

0.51%

Glenmark Q4FY16 Update 16May2016

Buy: Glenmark Pharmaceuticals Ltd.

Target

Phillip Capital

ROW (+36%) and LatAm (+34%) sales. US sales of US$ 97mn were inline with our estimates.CoreoperatingmarginadjustingforforexlossofRs840mnandonetime SitagliptinrelatedlitigationcostofRs650mn)compressedby~260bpsyoyto19.8%...

ICICI Securities Limited decreased Sell price target of Glenmark Pharmaceuticals Ltd. to 1570.0 on 19 Aug, 2025.